Buy Rating for Rockwell Medical Amid Growth Potential and Market Positioning

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Rockwell Med (RMTI – Research Report) today and set a price target of $3.00.

Ram Selvaraju has given his Buy rating due to a combination of factors that suggest potential growth for Rockwell Medical despite current challenges. The company has recently surpassed top-line revenue expectations for the first quarter of 2025, indicating strong performance. Although there is an anticipated revenue decline due to the loss of a major customer, Rockwell Medical is actively negotiating to retain some business and is focusing on expanding its customer base, particularly in the western United States.
Additionally, Rockwell Medical is pursuing multiple growth opportunities, including the development of new products like the single-use bicarbonate cartridge, which is expected to drive future revenue. The company is also the largest supplier of liquid bicarbonate concentrates in the U.S., positioning it well in the hemodialysis market. Despite a forecasted net loss for the upcoming years, the potential for top-line growth and gross margin improvement, along with a strong market position, supports the Buy rating.

Selvaraju covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Niagen Bioscience, and Emergent Biosolutions. According to TipRanks, Selvaraju has an average return of 7.7% and a 37.70% success rate on recommended stocks.

In another report released on May 13, Maxim Group also maintained a Buy rating on the stock with a $5.00 price target.